Na Cocer Peptides bin rayt am 
29 dez bifo
ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.
Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto mɛrɛsin, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.
Insay di wɔl, fɔ fat pasmak dɔn bi wan siriɔs pɔblik wɛlbɔdi prɔblɛm we de kam tranga wan, we gɛt fɔ du wit difrɛn sik dɛn we nɔ de mɛn lɛk di sik dɛn we de mek pɔsin in at ɛn di blɔd sik ɛn tayp 2 dayabitis, we mek fɔ fɛn fayn we fɔ lɛ pɔsin nɔ gɛt bɔku bɔku wet na di men tin we dɛn de pe atɛnshɔn pan na di mɛdikal risach. Survodutide, as wan nyu drɔg, dɔn sho se i kin wok fayn fɔ lɛ pɔsin lɔs in wet.
Ovaviu fɔ Survodutide
Survodutide na invεstigashכnal lכng-aktin dual agonist we de tכk tכk to di glukagon-lεk pεptida-1 rεsεpכta (GLP-1R) εn di glukכs-dipεndεnt insulinotropik polipεptida rεsεpכta (GIPR) wan tεm. I nid fɔ gi am wan tɛm nɔmɔ insay di wik, we de gi di sikman dɛn mɔ izi ɛn fɔ mek dɛn ebul fɔ fala di tritmɛnt fɔ lɔng tɛm.
Mekanism of Survodutide in Weyt Lɔs
Rigul di Enaji Intake
Apεtit sכpreshכn: afta i aktibכt GLP-1R εn GIPR, Survodutide de intarakt wit di sεntri nεv sεstem fכ rεgεl di haypothalamic apεtit kכntrכl sεnta. aktibכshכn fכ GLP-1R de akt pan vagal afferent fayb dεm fכ transmit signal to di arcuate nyuklios fכ di haypothalamus, we de inhεbit di aktvכti fכ agrep protin (AgRP) nyuron dεm, I kin aktibכt proopiomelanocortin (POMC) nyuron dεm bak, we de indyuz wan sεns fכ satiety εn ridyus fכd intake. aktibכshכn fכ GIPR kin εnhans dis apεtit-sכpreshכn ifekt bak tru di sem כ sinagεstik nyural path dεm, we de ridyus di bכdi in want fכ it εn kכnsekvεnt i de dכn di εnεji we i de it.
Altering food preferences: Insay wan hamster model of obesity ɛn dyslipidemia we dɛn indyuz bay fri-choice it, Survodutide bin ɛksɛrt wan spɛshal ifɛkt pan it prɛferɛns. We dɛn kɔmpia am wit di kɔntrol grup, Survodutide bin ridyus di it we gɛt bɔku fat ɛn wata we gɛt fruktɔs insay di 5 wik tritmɛnt tɛm, pan ɔl we i nɔ bin gɛt ɛni klia ifɛkt pan di it we dɛn bin de it rɛgyula it ɛn nɔmal wata. dis rεgεdyushכn ifekt pan fכd sεlεkshכn de εp fכ ridyus di intake fכ it dεm we gεt hכy kalori, kכntrכl di εnεji we pasmak na di sכs εn lay di fawndeshכn fכ weit lכs.
Rigul di ɛnaji we dɛn de spɛn
fכ protεkt fεt כksidεshכn: Survodutide de sho sכm sכm rεgεdyushכn ifekt dεm pan fεt mεtabolism. bay we i de aktibכt GLP-1R εn GIPR, i de infכlכw di fεt sεl mεtabolism tru mכltipכl signal path dεm. i de mek lipolysis insay adiposyt dεm, we de mek di fεt asid dεm we de kכmכt bכku; dis fεt asid dεm we dεn rilis de transpכt to maytochכndria fכ כksidεshכn, we de mek dεn εnεji spεnd. stכdi dεn sho se insay wan in vitro adiposyt mכdel, fכlכ Survodutide tritmεnt, di kכl εnzym dεm we de involv insay lipolysis εn fεt asid כksidεshכn, lεk hכmon-sεnsitiv laypas (HSL), carnitine palmitoyltransferase-1 (CPT-1), we sho se in mεkanism fכ akshכn fכ promuot fεt כksidεshכn involv fכ rεgεl di ki εnzym dεm na fεt mεtabolism.
inkrεs εnεji εkspεndishכn: apat frכm we i de akt dayrekt pan fεt sεl dεm fכ promuot fεt כksidεshכn, Survodutide kin inkrεs εnεji εkspεndishכn bak bay we i de infכlכw sistεmik εnεji mεtabolism. insay animal εkspεriεns, dεn bin si se pan כl we di aktiviti lεvεl dεm fכ animal dεm nכ chenj bכku afta Survodutide administreshכn, dεn basal mεtabolik rεt inkrεs. dis na bikoz fכ di kכmprεhεnsiv ifekt dεm we di dכg gεt pan mכltipכl tisu dεm εn כgan dεm, we de εnhans mεtabolik aktiviti na di liva εn skel mכsul, we de mek di enεji kכnsכmshכn inkrεs we i de rεst εn achy wan enεji dεfisit, we de mek yu lכs di wet.
rεgulεshכn fכ glukכs mεtabolism εn insulin sεnsitiviti
Fɔ mek di insulin rɛsistɛns bɛtɛ: Bɔku tɛm, di wan dɛn we fat kin gɛt insulin rɛsistɛns, we kin afɛkt di nɔmal ɛnaji mɛtabolism ɛn yutilizeshɔn. Survodutide de aktibכt GLP-1R fכ mek insulin sekreshכn we i de εnhans insulin sεnsitiviti, we de mek di bכdi in rεspכns to insulin bכku. Insay stɔdi we dɛn du pan pasɛnt dɛn we gɛt tayp 2 dayabitis, afta 16 wiks we dɛn dɔn trit di Survodutide, di plasma insulin lɛvɛl ɛn di insulin rɛsistɛns indeks (HOMA-IR) bin ridyus bad bad wan, we sho se di drɔg kin ɛp fɔ mek insulin rɛsistɛns bɛtɛ, we kin mek di sɛl dɛn ebul fɔ tek ɛn yuz glukɔs fayn fayn wan, i kin mek i nɔ chenj to fat, ɛn i kin ɛp fɔ kɔntrol di wet.
fכ rεgεl di blכd glukכs lεvεl: Survodutide in dual rεsεpכta agonist akshכn de gi am wan yכnik advantej fכ rεgεl di blכd glukכs lεvεl. GLP-1R agonism de promuot insulin sekreshכn we i de inhibit glukagon rilis, we de mek di blכd glukכs lεvεl dכn. GIPR agonism de promuot insulin sekreshכn bak כnda fysiolojikal kכndishכn dεm. tru di sinagεstik ifekt dεm, i kin bεtε mεnten di blכd glukכs lεvεl stebul. di blכd shuga lεvεl we stebul de εp fכ ridyus angri εn inkrεs εnεji stכrej we kכz fכ di blɔd shuga fכ chenj, indaykt wan de εksyεrt fayn ifekt pan di wεt kכntrכl.
Di Rol we Survodutide de ple fɔ lɛ pɔsin lɔs di wet
Sigifikant weit lɔs ifɛkt: Insay wan randomiz, dɛbul-blaynd, plasɛbo-kɔntrol Faz 2 doz-fayndin trayal we dɛn tɔch ɔbis pasɛnt dɛn, 387 big pipul dɛn we ol 18–75 ia wit wit bɔdi mas indeks (BMI) ≥27 kg/m² ɛn nɔ dayabitis nɔ bin asaynd randomly to fayv grup, we bin de gɛt ɛvri wik sabkyutan injɛkshɔn fɔ Survodutide (0.6, 2.4, 3.6, ɔ 4.8 mg) ɔ plasɛbo fɔ 46 wik tritmɛnt tɛm. Di risal sho se na wik 46, di pasɛnt dɛn we dɛn trit wit 4.8 mg Survodutide bin gɛt avɛrej wet lɔs we na 18.7% kɔmpia to di plesibo grup, wit wan statistically signifyant difrɛns pan weight ridɔkshɔn. Insay wan ɔda stɔdi we dɛn bin de tɔch pasɛnt dɛn we gɛt tayp 2 dayabitis ɛn fat, Survodutide tritmɛnt bin rili mek dɛn lɔs dɛn wet we bin dipen pan di doz afta 16 wik, wit maksimal ridyushɔn we na 8.7%. apat frכm dat, Survodutide pan doz we na ≥1.8 mg wan tεm insay wik prodyuz big weit lכs pas di kכmכn yus GLP-1 rεsεptכr agonist Semaglutid, we rεsult in weit rεdukshכn 5.3%.
Jɛnda ɛn BMI difrɛns: Fɔda sabgrup analisis dɛn sho se di wet-lɔs ifɛkt dɛn we Survodutide gɛt bin difrɛn akɔdin to difrɛn jɛnɛral ɛn BMI lɛvɛl dɛn. Insay di trayal we wi bin dɔn tɔk bɔt we dɛn bin de tɔch di wan dɛn we fat, na wik 46, di avɛrej weit lɔs pasɛnt (17.0%) na di 4.8 mg Survodutide grup bin ay pan uman dɛn pas man dɛn (11.9%); akraos difrεn BMI sכbgrup dεm, pasεnshכn dεm wit BMI < 30 kg/m² bin gɛt rili ay weit lɔs pasɛnt (19.1%), bɔt di absɔlɔb wet lɔs valyu dɛn nɔ bin rili difrɛn akɔdin to BMI sabgrup dɛn. Dis sho se insay klinik prɛktis, dɔktɔ dɛn kin ebul fɔ ɛstimat di wet lɔs ifɛkt dɛn we Survodutide gɛt mɔ kɔrɛkt wan bay we dɛn de tink bɔt tin dɛn lɛk di pɔsin in jɛnɛral ɛn BMI.
Bodi Fat Distribushכn εn Mεtabolik Improvement
fכ ridyus di vishכnal fεt: Survodutide nכ de כnli ridyus di tכtal bכdi wet bכt i gεt fayn impak pan di bכdi fεt distribushכn. we di vishכnal fεt we de kכmכt pasmak de kכlכsכl wit di divεlכpmεnt fכ difrεn mεtabolik sik dεm. insay rilevεnt stכdi dεm, afta dεn gεt Survodutide tritmεnt fכ wan tεm, di pasεnshכn dεm bin εkspiriεns sכm rεdukshכn na di vishכnal fεt εria. dis na biכs di dכg de mek di vishכnal fεt brok εn כksidεshכn, i de impruv in mεtabolism εn dat de ridyus di mεtabolik risk dεm we de asai fכ di vishכnal fεt we pasmak.
Fɔ mek di lipid nɔ fayn: Bɔku tɛm, di wan dɛn we fat kin gɛt di lipid we nɔ de wok fayn, lɛk aypa kɔlɔstrel ɛn aypa triglisɛrɛydemia. Survodutide nכ de כnli εp fכ lכs di wet bכt i de impruv di lipid paramita dεm. Insay animal ɛkspiriɛns, fat hamsta dɛn we dɛn trit wit Survodutide sho se di plasma tɔtal kɔlɔstrel lɛvɛl dɔn rili ridyus, wit 41% dikrishɔn na di Survodutide grup ɛn 24% dikrishɔn na di semaglutide grup. Dɛn bin si di sem kayn rizɔlt insay mɔtalman trayal, usay Survodutide tritmɛnt bin mek di triglisɛrɛyd lɛvɛl go dɔŋ bad bad wan. I bin de du bak difrɛn digri dɛn pan rigyuletɔri ifɛkt pan lɔw-dɛnsity lipoprotein kɔlɔstrel (LDL-C) ɛn ay-dɛnsity lipoprotein kɔlɔstrel (HDL-C), we ɛp fɔ kɔrɛkt dislipidemia ɛn ridyus di risk fɔ gɛt sik dɛn we de ambɔg di at ɛn di blɔd.
Efεkt dεm pan di kכdivaskyul risk fכktכr dεm
Fɔ mek blɔd prɛshɔn go dɔŋ: Fɔ fat na wan pan di men tin dɛn we kin mek pɔsin gɛt ay blɔd prɛshɔn. Insay klinik trayal we dɛn bin de tɔch di wan dɛn we fat, afta 46 wiks we dɛn bin de trit di Survodutide, ɔl tu di sistolik blɔd prɛshɔn (SBP) ɛn dayastolik blɔd prɛshɔn (DBP) sho se dɛn dɔn ridyus bɔku bɔku wan. We yu kɔmpia am wit di plasɛbo grup, di 4.8 mg Survodutide grup sho maksimal avɛrej ridyushɔn fɔ 10.2 mmHg insay SBP ɛn 4.8 mmHg insay DBP. Dis ifekt we de mek di blɔd prɛshɔn go dɔŋ kin gɛt fɔ du wit bɔku tin dɛn, lɛk di we aw Survodutide de mek di vaskyuɛl ɛndoteyl wok fayn, we i de ridyus di simpatik nɛv dɛn we de wok, ɛn we i de lɔs di wet, we dɛn ɔl togɛda de ɛp fɔ ridyus di risk fɔ gɛt di sik we de na di at ɛn di blɔd.
impruv di vaskulכr fכnshכn: Survodutide kin εksyεrt protεktiv ifekt dεm bak pan di kכdivaskyul sistεm bay we i de impruv di fכnshכn fכ di vaskul εndoteyl sεl dεm. fכ fala Survodutide administreshכn, di rilis fכ nitric oxide (NO) bay vaskulכr εndoteyl sεl dεm de inkrεs. NO na impɔtant vasodilator we de mek di blɔd vesel dɛn big, i de ridyus di vaskul dɛn we nɔ de wok, ɛn i de mek di blɔd go fayn fayn wan. di dכg kin inhεbit inflammatory rεspכns dεm εn כksidεtiv strεs bak, we de ridyus di vaskulכr wכl dεm we de dכn εn fכ mεnten di vaskulεr hεlth mכr.
Aplikeshɔn fɔ Survodutide insay Wɛt Lɔs
Di pipul dɛn we dɛn de tɔk bɔt
Pipul dɛn we fat ɛn we gɛt bɔku bɔku wet: Fɔ pipul dɛn we fat ɔ we gɛt bɔku bɔku bɔdi we gɛt BMI ≥ 27 kg/m², Survodutide dɔn sho se i gɛt gud we fɔ lɔs dɛn wet. Ɔl tu di pasɛnt dɛn we gɛt simpul fat ɛn di wan dɛn we fat we gɛt ɔda mɛtabolik dizayd lɛk tayp 2 dayabitis ɔ dislipidemia kin bɛnifit frɔm Survodutide tritmɛnt. Insay klinik trayal, fat pasɛnt dɛn akɔdin to difrɛn ej grup dɛn (18–75 ia) sho gud rispɔns to Survodutide, we sho se dɛn gɛt bɔku bɔku pipul dɛn we fit fɔ gɛt am.
Di wan dɛn we fat we gɛt fɔ du wit sɔm patikyula sik dɛn: Apat frɔm di jenɛral pipul dɛn we fat, Survodutide na tritmɛnt opshɔn bak fɔ fat we sɔm patikyula sik dɛn kin mek, lɛk polycystic ovary syndrome (PCOS), usay fat ɛn mɛtabolik dizayd kin de togɛda bɔku tɛm.
fכ mek di ifekt dεm fכ lכs di wet bכku εn fכ impruv mεtabolik stetכs, dεn kin yuz Survodutide wit כda tritmεnt mεtכd dεm. We dɛn kam togɛda wit layf stayl intavɛnshɔn (di it kɔntrol ɛn ɛksɛsayz), dɛn kin gɛt sinajɛstik ifɛkt. Insay klinik trayal, di pasɛnt dɛn we bin gɛt Survodutide tritmɛnt we dɛn kam togɛda wit ɛksɛsayz ɔltɛm ɛn balans it bin gɛt mɔ wet lɔs ɛn mɔ impɔtant improvement pan mɛtabolik mak dɛn. Apat frɔm dat, fɔ di wan dɛn we gɛt tayp 2 dayabitis ɛn we fat pasmak, dɛn kin yuz Survodutide togɛda wit ɔda antidiabetic mɛrɛsin dɛn lɛk metformin fɔ kɔntrol di blɔd shuga lɛvɛl ɛn dɛn kin ebul fɔ manej dɛn wet fayn fayn wan.
Dɔn
fכ sכmari, Survodutide, as nכvel dual rεsεptכr agonist, na bεnεfit fכ weit lכs. di yכŋ mεkanism we i de du nכto nכmכ de ridyus di wet fayn fayn wan bכt i de impruv di bכdi fεt distribushכn, rεgεl glukכs εn lipid mεtabolism, εn ridyus di kכdivaskyul risk fכktכ dεm.
Sos dɛn we dɛn pul
[1] Briand F, Ɔgɔstin R, Blɛymɛl K, ɛn ɔda pipul dɛn. 7279 Survodutide εn Semaglutid כl tu de indyuz weit lכs bכt sho difrεnt ifekt dεm pan fכd prεfrεns εn dislipidemia in di fri chכys dayεt-indyuz כbis hamsta mכdel[J]. J ɔ rnal ov di Ɛndokrin Sɔsayti, 2024,8(Saplimɛnt_1):bvae134-bvae163.DOI:10.1210/jendso/bvae163.034.
[2] Le Roux C, Steen O, Lukas K. J., ɛn ɔda pipul dɛn. Survodutide, we na glukagon rεsεptכr/GLP-1 rεsεptכr (GCGR/GLP-1R) dual agonist, de impruv di kכdiכmεtabolik paramita dεm insay big pipul dεm we fat: analisis fכ wan plasεbo-kכntrol, randomizεd fεz 2 trayal[J]. Yuropian At Jɔnal, 2024,45(Saplimɛnt_1):ehae666-ehae2895.DOI:10.1093/eurheartj/ehae666.2895.
[3] Blüher M, Rosenstɔk J, Hoefler J, ɛn ɔda pipul dɛn. Doz-rεspכns ifekt pan HbA(1c) εn bכdi wεyt rεdukshכn fכ survodutide, we na dual glucagon/GLP-1 rεsεptכr agonist, kכmpεr wit plasεbo εn opin-lεbul semaglutide in pipul dεm wit tayp 2 dayabεtis: wan randomizεd klinik trial[J]. Diabetolojia, 2024,67(3):470-482.DOI:10.1007/s00125-023-06053-9.
[4] Mei Z, Pu J, Shao Z. Tu Trayal fɔ Tɛrapi fɔ MASH wit Liva Faybrosis[J]. Nyu Ingland Jɔnal fɔ Mɛdisin, 2024,391(15):1461-1462.DOI:10.1056/NEJMc2411003.
[5] Sanyal A. J., Bedossa P., Fraessdorf M, ɛn ɔda pipul dɛn. A Faz 2 Randomized Trayal fɔ Survodutide in MASH ɛn Fibrosis[J]. Nyu Ingland Jɔnal fɔ Mɛdisin, 2024,391(4):311-319.DOI:10.1056/NEJMoa2401755.
[6] Le Roux CW, Steen O, Lukas K. J., ɛn ɔda pipul dɛn. Glucagon εn GLP-1 rεsεptכr dual agonist survodutide fכ obesiti: wan randomizεd, dכbl-blaynd, plasεbo-kכntrol, dכz-fεnd fεz 2 trayal.[J]. Di Lancet we dɛn kɔl. Dayabitis & Ɛndokrinɔlɔji, 2024. https://api.semanticscholar.org/CorpusID:267503510
[7] Lawitz E. J., Fraessdorf M, Nɛf G. W., ɛn ɔda pipul dɛn. OS-119 Survodutide (BI 456906), wan glukagon rεsεptכr/glukagon lεk pεptida-1 rεsεptכr (GCGR/GLP-1R) dual agonist, insay pipul dεm we gεt kכmpεns εn dεkכmpεns sirosis: wan mכltinashכnal, opin-lεbul, fεz 1 trayal[J]. J ɔ rnal ɔ f Ɛpat ɔ l ɔ ji, 2024. https://api.semanticscholar.org/CorpusID:270457365
[8] Le Roux CW, Steen O, Lukas K. J., ɛn ɔda pipul dɛn. 6926 Sabgrup Analysis bay Jεnda εn Bכdi Mas Indeks (BMI) in Pipul dεm we De Liv wit Ovaweyt/Obesiti in di Survodutide, wan Glucagon/GLP-1 Risεptor Dual Agonist, Faz II Trayal[J]. J ɔ rnal ov di Ɛndokrin Sɔsayti, 2024,8(Saplimɛnt_1):bvae133-bvae163.DOI:10.1210/jendso/bvae163.033.
Prodak we de fɔ yuz fɔ risach nɔmɔ:
